Mobile

Safety and efficacy of MPDL3280A (anti-PDL1 antibody) compared to gemcitabine + platinum-based chemotherapy in previously untreated patients with metastatic, squamous, PD-L1-selected, non-small cell l...

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-003106-33

Safety and efficacy of MPDL3280A (anti-PDL1 antibody) compared to gemcitabine + platinum-based chemotherapy in previously untreated patients with metastatic, squamous, PD-L1-selected, non-small cell lung cancer

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective for this study is to evaluate the efficacy of MPDL3280A compared with carboplatin or cisplatin + gemcitabine in chemotherapy-naive patients with Stage IV squamous NSCLC, as measured by investigator-assessed PFS according to RECIST v1.1

Critère d'inclusion

  • Previously untreated Stage IV, Squamous, Non-Small Cell Lung Cancer

Liens